308 related articles for article (PubMed ID: 29885481)
1. Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient.
Haratake N; Tagawa T; Hirai F; Toyokawa G; Miyazaki R; Maehara Y
J Thorac Oncol; 2018 Nov; 13(11):1798-1799. PubMed ID: 29885481
[No Abstract] [Full Text] [Related]
2. Pembrolizumab induced toxic epidermal necrolysis.
Kumar R; Bhandari S
Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
[No Abstract] [Full Text] [Related]
3. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer.
Riano I; Cristancho C; Treadwell T
J Investig Med High Impact Case Rep; 2020; 8():2324709620914796. PubMed ID: 32207346
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.
Saw S; Lee HY; Ng QS
Eur J Cancer; 2017 Aug; 81():237-239. PubMed ID: 28438440
[No Abstract] [Full Text] [Related]
6. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
Robinson S; Saleh J; Curry J; Mudaliar K
Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
[TBL] [Abstract][Full Text] [Related]
8. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
[No Abstract] [Full Text] [Related]
9. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
[No Abstract] [Full Text] [Related]
10. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Ziemer CM; Miedema J; Smith CJ; Liu Z; Thomas NE; Googe PB
Am J Dermatopathol; 2021 Apr; 43(4):318-320. PubMed ID: 33055536
[No Abstract] [Full Text] [Related]
12. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib.
Nühnen VP; Schön MP; Mössner R
J Dtsch Dermatol Ges; 2018 Feb; 16(2):199-201. PubMed ID: 29328518
[No Abstract] [Full Text] [Related]
13. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor.
Horii M; Kobayashi T; Maeda S; Takehara K; Matsushita T
J Dermatol; 2019 Nov; 46(11):e434-e436. PubMed ID: 31342541
[No Abstract] [Full Text] [Related]
14. Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications.
Ryu S; Jun I; Kim TI; Seo KY; Kim EK
Ocul Immunol Inflamm; 2022 Aug; 30(6):1533-1535. PubMed ID: 33826467
[TBL] [Abstract][Full Text] [Related]
15. Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction.
Shi CR; Shaughnessy M; Sehgal K; Clark JR; Reynolds KL; Toyohara J; Chen ST
Int J Dermatol; 2023 Oct; 62(10):1292-1294. PubMed ID: 36628976
[No Abstract] [Full Text] [Related]
16. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.
Lomax AJ; McQuillan PIA; Hall A; McArthur GA
Intern Med J; 2019 Aug; 49(8):1051-1053. PubMed ID: 31387152
[No Abstract] [Full Text] [Related]
17. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction.
Neema S; Sathu S; Vasudevan B; Shreshta S; Bhatt S; K L
Indian J Dermatol Venereol Leprol; 2023; 89(4):589-591. PubMed ID: 37067146
[No Abstract] [Full Text] [Related]
18. Depletion of regulatory FoxP3
Amakata M; Teraki Y
Int J Dermatol; 2019 Dec; 58(12):e247-e249. PubMed ID: 31334834
[No Abstract] [Full Text] [Related]
19. Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitunumab.
Pantano F; Silletta M; Iovieno A; Vincenzi B; Santini D; Galluzzo S; Bonini S; Tonini G
Int J Colorectal Dis; 2009 Oct; 24(10):1247-8. PubMed ID: 19225787
[No Abstract] [Full Text] [Related]
20. [Stevens-Johnson syndrome concurrent with primary Epstein-Barr virus infection].
Brunet-Possenti F; Steff M; Marinho E; Crickx B; Descamps V
Ann Dermatol Venereol; 2013 Feb; 140(2):112-5. PubMed ID: 23395492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
